<DOC>
	<DOCNO>NCT00423826</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy total-body irradiation donor umbilical cord blood stem cell transplant help stop growth cancer abnormal cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer abnormal cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus mycophenolate mofetil transplant may stop happen . PURPOSE : This clinical trial study well umbilical cord blood stem cell transplant work treat patient hematologic cancer disease .</brief_summary>
	<brief_title>Umbilical Cord Blood Stem Cell Transplant Treating Patients With Hematologic Cancer Other Disease</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy double umbilical cord blood stem cell transplantation use condition regimen comprise low dos busulfan fludarabine phosphate low-dose total body irradiation , term stem cell engraftment 60 day post transplantation , patient hematologic cancer disease . - Determine merit conduct large , comparative study regimen . Secondary - Determine mortality within 100 day transplantation patient . OUTLINE : This pilot study . - Reduced-intensity conditioning regimen : Patients receive busulfan IV 3 hour day -9 -8 fludarabine phosphate IV day -7 -3 . Patients undergo low-dose total body irradiation day 0 . - Graft-versus-host disease prophylaxis : Patients receive tacrolimus IV twice daily mycophenolate orally IV three time daily begin day -3 . - CNS prophylaxis and/or treatment : Patients history CNS involvement receive prophylactic cytarabine ( Ara-C ) intrathecally ( IT ) prior transplant . Patients also undergo lumbar puncture ( LP ) test active CNS disease . Patients cerebrospinal fluid positive leukemia receive Ara-C IT every 2-3 day repeat LP show remain leukemic cell . Three day last LP one final dose Ara-C , patient begin condition regimen . - Double umbilical cord blood ( UCB ) donor stem cell transplantation ( SCT ) : Patients undergo double UCB donor SCT day 0 . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Acute myeloid leukemia meeting follow criterion : M0M7 histologic subtypes FrenchAmericanBritish classification Previously treat disease Meets 1 follow criterion : Persistent disease evidence 530 % persistent blast bone marrow induction salvage therapy In second subsequent complete remission ( CR ) In first CR 1 follow highrisk feature : Philadelphia chromosome present Noncorebinding factor type chromosomal abnormality Myelodysplastic syndromes 1 follow International Prognostic Scoring System ( IPSS ) score : Intermediate1 Intermediate2 Highrisk score transfusion dependence Chronic myelogenous leukemia meeting 1 follow criterion : In accelerate blastic phase Failed prior imatinib mesylate therapy Acute lymphoblastic leukemia meeting 1 follow criterion : In first CR follow highrisk feature : Philadelphia chromosome present Translocation ( 4 ; 11 ) present WBC &gt; 30,000/mm³ ( adult patient ) More 4 week initiation treatment require achieve CR ( adult patient ) DNA index near haploid ( N=23 chromosome ) ( pediatric patient ) In second subsequent CR Persistent disease evidence 520 % persistent blast bone marrow induction salvage therapy Hodgkin 's nonHodgkin 's lymphoma meeting follow criterion : Recurrent refractory disease Tumor ≤ 5 cm diameter Myeloma plasma cell neoplasm meet 1 follow stag criterion : Stage III presentation Stage III presentation Not respond OR progress firstline therapy Chronic lymphocytic leukemia Waldenstrom 's macroglobulinemia refractory progressive disease firstline therapy No 56/6 HLAmatched relate 78/8 HLAmatched unrelated marrow peripheral blood stem cell donor available No single 46/6 HLAA , B , DRB1matched umbilical cord blood unit ≥ 3.5 x 10^7 nucleated cells/kg available PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky Lansky PS 70100 % Not pregnant Fertile patient must use effective contraception prior study participation HIV negative Bilirubin &lt; 3.0 mg/dL AST ALT ≤ 3 time upper limit normal Creatinine &lt; 2.0 mg/dL OR creatinine clearance &gt; 50 mL/min Cardiac ejection fraction &gt; 50 % echocardiogram OR shorten fraction &gt; 27 % No uncontrolled symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia FEV_1 &gt; 50 % normal Forced vital capacity &gt; 50 % normal DLCO normal Oxygen saturation &gt; 92 % room air ( patient &lt; 5 year age ) No history allergic reaction attribute compound similar chemical biological composition busulfan fludarabine phosphate No ongoing active infection No psychiatric illness social situation would preclude study compliance No uncontrolled illness PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior concurrent surgery At least 4 week since prior concurrent investigational commercial agent therapy malignancy , include chemotherapy , biologic therapy , radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>secondary myelofibrosis</keyword>
</DOC>